CTLA4 and digestive system disorder: For the CTLA-4 inhibitor ipilimumab, the three most common tissue or organ disorders were ‘neoplasms benign, malignant and unspecified’ (1,781 cases, 21.97%), ‘gastrointestinal disorders’ (1,233 cases, 15.21%) and ‘respiratory, thoracic and mediastinal disorders’ (849 cases, 10.47%) (Fig. 4 and Supplementary Figure S3C).